Certara, Inc. (HAM:700)
Germany
· Delayed Price · Currency is EUR | Market Cap | 953.53M |
| Revenue (ttm) | 356.72M |
| Net Income (ttm) | -1.36M |
| Shares Out | n/a |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | 15.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 50 |
| Open | 5.62 |
| Previous Close | 5.27 |
| Day's Range | 5.62 - 5.76 |
| 52-Week Range | 5.27 - 11.63 |
| Beta | n/a |
| RSI | 38.55 |
| Earnings Date | Feb 26, 2026 |
About Certara
Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and tr... [Read more]
Financial Performance
In 2025, Certara's revenue was $418.84 million, an increase of 8.75% compared to the previous year's $385.15 million. Losses were -$1.60 million, -86.76% less than in 2024.
Financial numbers in USD Financial StatementsNews
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the followi...
Certara, Inc. (CERT) Q4 2025 Earnings Call Transcript
Certara, Inc. (CERT) Q4 2025 Earnings Call Transcript
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj.
The London Company Small Cap Q4 2025 Performance And Trades
The London Company Small Cap portfolio increased 2.7% (2.5% net) during the quarter vs. a 2.2% increase in the Russell 2000 Index. Contributors to relative performance were White Mountains Insurance G...
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth q...
Wasatch Core Growth Fund Q4 2025 Performance Review
Shift4 Payments' stock was down after a competitor reported disappointing results, raising concerns for the industry. While Trex Co. is facing some current challenges, we still view Trex as a high-qua...
Cerrado Gold Inc. (CERT:CA) Discusses Purported Unfavourable Opinion of Environmental Impact Assessment for Lagoa Salgada Project Transcript
Cerrado Gold Inc. (CERT:CA) Discusses Purported Unfavourable Opinion of Environmental Impact Assessment for Lagoa Salgada Project Transcript
Certara Appoints Jon Resnick as Chief Executive Officer
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth
Cerrado Gold Inc. (CERT:CA) Q3 2025 Earnings Call Transcript
Cerrado Gold Inc. (CERT:CA) Q3 2025 Earnings Call Transcript
Touchstone Small Company Fund Q3 2025 Performance Review
The Touchstone Small Company Fund underperformed its benchmark, the Russell 2000 Index, for the quarter ended September 30, 2025. Among the Fund's top-performing sectors in terms of adding value were ...
Certara, Inc. (CERT) Presents at Stephens Annual Investment Conference 2025 Transcript
Certara, Inc. ( CERT) Stephens Annual Investment Conference 2025 November 18, 2025 2:00 PM EST Company Participants John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Confer...
Certara, Inc. (CERT) Presents at Jefferies London Healthcare Conference 2025 Transcript
Certara, Inc. ( CERT) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants William Feehery - CEO & Director Conference Call Participants David Windley - Jeff...
Certara, Inc. (CERT) Q3 2025 Earnings Call Transcript
Certara, Inc. ( CERT) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants William Feehery - CEO & Director John Gallagher - SVP, Principal Accounting Officer & Chief Financial Off...
Certara Reports Third Quarter 2025 Financial Results
RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal ye...
Certara Automates Scientific Workflows with Phoenix® Cloud
RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module...
Certara Expands Biosimulation Market with AI-Driven QSP Platform
RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quanti...
Certara Scientists are Among the Topmost Cited Biopharma Researchers
RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research.
Why Investors Should Consider Certara Again
Certara posted strong Q1 and Q2 results, with revenue growth and non-GAAP EPS exceeding expectations, driven by biosimulation software and services. Certara's AI-enabled platforms, including the upcom...
Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025
RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 afte...
Final Trade: CERT, GDX, IWM, MPC
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Certara, Inc. (CERT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Certara, Inc. (NASDAQ:CERT) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 12:20 PM EDT Company Participants John Gallagher - SVP, Principal Accounting Officer & Chief Fin...
Certara, Inc. (CERT) Presents At Baird Global Healthcare Conference 2025 (Transcript)
Certara, Inc. (NASDAQ:CERT) Baird Global Healthcare Conference 2025 September 9, 2025 10:15 AM EDT Company Participants William Feehery - CEO & Director John Gallagher - SVP, Principal Accounting Off...
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the availability of Pinnacle 21 Enterprise Plus.